ADIOS – adaptive ocrelizumab dosing study
Dear MS Academy Member,
We are exploring a funding application to perform an Adaptive Ocrelizumab Dosing Study or ADIOS trial. The idea is to try and adjust the dosing regimen of ocrelizumab to derisk some of the emerging adverse events associated with long-term B cell depletion. Would you be interested in participating? If yes, do you mind completing the following survey to see if we can get some kind of consensus around the trial design?
Prof Gavin Giovannoni
Adios Study Survey
ADIOS refers to the ADaptIve Ocrelizumab dosing Study.
The ADIOS study proposes to explore whether or not we can adjust the dose of ocrelizumab to make it safer (lower rate of hypogammaglobulinaemia and fewer infections), allow vaccinations (for example SARS-CoV-2 vaccine), reduce healthcare utilisation (fewer infusions and lower costs) without necessarily compromising its efficacy.
This survey is to explore some issues around the principles of the study, our proposed design and whether or not you want to participate. The figure below is a rough outline of the proposed study.
Encouraging excellence, developing leaders, inspiring change
MS Academy was established five years ago and in that time has accomplished a huge amount. The six different levels of specialist MS training are dedicated to case-based learning and practical application of cutting edge research. Home to national programme Raising the Bar and the fantastic workstream content it is producing, this is an exciting Academy to belong to.